{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:46:09Z","timestamp":1787827569050,"version":"build-2784847793"},"reference-count":156,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Genentech, Inc., a member of the Roche Group, for third-party writing assistance, which was provided by Dionne Turnbull, PhD of Envision Pharma Group"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.1080\/17425247.2023.2166927","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T03:46:54Z","timestamp":1673495214000},"page":"223-240","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Intraocular delivery considerations of ocular biologic products and key preclinical determinations"],"prefix":"10.1080","volume":"20","author":[{"given":"Patrick","family":"Hughes","sequence":"first","affiliation":[{"name":"Pharmaceutical Development, Visus Therapeutics, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen M.","family":"Rivers","sequence":"additional","affiliation":[{"name":"Biomaterials and Drug Delivery, Medical Aesthetics, AbbVie Inc, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Bantseev","sequence":"additional","affiliation":[{"name":"Department of Safety Assessment, Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wan","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Safety Assessment, Genentech, Inc, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Christian","family":"Mahler","sequence":"additional","affiliation":[{"name":"Ten23 Health Ag, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Gupta","sequence":"additional","affiliation":[{"name":"Non-clinical Development Immunology, AbbVie Inc, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0200"},{"key":"cit0002","unstructured":"Kiernan DF, Lim JI Topical drug delivery for posterior segment disease. Retina Today. 2010 [cited 2021 Dec 15]:[https:\/\/retinatoday.com\/articles\/2010-may-june\/topical-drug-delivery-for-posterior-segment-disease"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030269"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2689-1"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.09.004"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.4155\/tde.10.40"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.5301\/EJO.2010.6112"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S264926"},{"key":"cit0009","unstructured":"Wilson CG, Semenova EM, Hughes P, et al. Enhancement in Drug Delivery, ed. E. Touitou and B. W. Barry. Boca Raton FL: Taylor & Francis; 2007. p. 473."},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9694-0"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1986.2.67"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600721108"},{"key":"cit0013","first-page":"85","volume-title":"Butterworth-Heinemann","author":"Fatt I","year":"1992"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0091"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(79)90158-9"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.024"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317337"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315933"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.060"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.134874"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"cit0022","doi-asserted-by":"crossref","unstructured":"Bakri SJ, Thorne JE, Ho AC, et al. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2019 Jan;126(1):55\u201363.","DOI":"10.1016\/j.ophtha.2018.07.028"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9718-9"},{"key":"cit0025","unstructured":"ClinicalTrials.gov. NCT03630952. Efficacy and safety trial of conbercept intravitreal injection for neovascular AMD (PANDA-2): u.S. National Library of Medicine; 2021 [cited 2021 Jun 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03630952"},{"key":"cit0026","unstructured":"Krader CG DARPin delivers promising results in phase II study of exudative AMD. Ophthalmology Times. 2014 [cited 2014 Sept 15]:[https:\/\/www.ophthalmologytimes.com\/view\/darpin-delivers-promising-results-phase-ii-study-exudative-amd"},{"key":"cit0027","unstructured":"Partners M. Allergan and Molecular Partners announce topline safety results from MAPLE study of Abicipar pegol 2019 [cited 2019 Apr 2]:[https:\/\/www.molecularpartners.com\/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol\/"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.031"},{"key":"cit0029","volume-title":"OPT-302 (VEGF-C\/D \u2018Trap\u2019) combination treatment in nAMD and DME. American Society of Retina Specialists","author":"Baldwin M","year":"2019"},{"key":"cit0030","unstructured":"ClinicalTrials.gov. NCT03345082. A dose ranging study of OPT-302 with ranibizumab in neovascular (wet) AMD: u.S. National Library of Medicine; 2021 [cited 2021 Aug 08]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345082"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.88"},{"issue":"9","key":"cit0032","first-page":"1508.e1","volume":"113","author":"Chakravarthy U","year":"2006","journal-title":"Ophthalmology"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.03.004"},{"key":"cit0038","unstructured":"Pharmaceuticals A. Phase 2 study published in Ophthalmology highlights efficacy and safety data of intravitreal APL-2 for geographic atrophy secondary to age-related macular degeneration 2019 [cited 2019 Sept 18]:[https:\/\/investors.apellis.com\/news-releases\/news-release-details\/phase-2-study-published-ophthalmology-highlights-efficacy-and"},{"key":"cit0039","unstructured":"Pharmaceuticals A. Apellis pharmaceuticals provides update on its phase 3 program for patients with geographic atrophy 2018 [cited 2018 Dec 20]:[https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-pharmaceuticals-provides-update-its-phase-3-program"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12419"},{"key":"cit0041","unstructured":"ClinicalTrials.gov. NCT01157065. Evaluation of AL-78898A in exudative age-related macular degeneration (RACE): u.S. National Library of Medicine; 2013 [cited 2021 Aug 05]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01157065"},{"key":"cit0042","unstructured":"Ophthotech Press Release. Ophthotech announces results from third phase 3 trial of Fovista\u00ae in wet age-related macular degeneration 2017 [cited 2022 Jul 24. Available from: http:\/\/www.businesswire.com\/news\/home\/20170814005286\/en\/"},{"key":"cit0043","unstructured":"Lenier SAPL-2 slows growth of GA in phase II safety and efficacy trial. Modern Retina. 2018 [cited 2018 Feb 26]:[https:\/\/www.modernretina.com\/view\/apl-2-slows-growth-ga-phase-ii-safety-and-efficacy-trial"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.044"},{"key":"cit0046","unstructured":"F. Hoffman-La Roche Ltd. Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration 2017 [cited 2017 Sept 7]:[https:\/\/www.roche.com\/media\/releases\/med-cor-2017-09-08b.htm"},{"key":"cit0047","unstructured":"Ophthalmics A. Allegro Ophthalmics announces positive topline vision results of phase 2 study evaluating risuteganib in patients with intermediate dry age-related macular degeneration 2019 [cited 2019 Jun 4]:[https:\/\/www.allegroeye.com\/allegro-ophthalmics-expands-its-anti-integrin-portfolio-with-new-front-of-the-eye-drug-candidate-alg-1007-for-the-treatment-of-dry-eye-disease-3-2-2\/"},{"key":"cit0048","unstructured":"Regeneron. Regeneron provides update on Eylea\u00ae (aflibercept) injection and nesvacumab (Ang2 antibody) combination program 2017 [cited 2017 Nov 27]:[https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-eylear-aflibercept-injection-and"},{"key":"cit0049","unstructured":"Oxurion. Oxurion NV reports first patient dosed in phase 2 study evaluating THR-149 for treatment of diabetic macular edema (DME) 2020 [cited 2020 Sept 1]:[https:\/\/www.oxurion.com\/content\/oxurion-nv-reports-first-patient-dosed-phase-2-study-evaluating-thr-149-treatment-diabetic"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699"},{"key":"cit0051","unstructured":"Genentech Inc. New STAIRWAY study data shows potential for extended durability with faricimab in wet age-related macular degeneration (AMD) 2018 [https:\/\/www.gene.com\/media\/press-releases\/14762\/2018-10-27\/new-stairway-study-data-shows-potential-"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbon.2022.09.045"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2021.101156"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2013.821564"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2015.11.002"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119523"},{"key":"cit0057","unstructured":"Carpenter J. In: Development of stable formulations of therapeutic proteins for drug delivery systems. AAPS workshop on protein aggregation and immunogenicity, Arlington, VA. July 10\u201312. Breckenbridge: CO2012."},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026498209874"},{"issue":"13","key":"cit0059","first-page":"3433","volume":"55","author":"Roguska M","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.2165\/11530970-000000000-00000"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0159-x"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/0168-3659(93)90182-5"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20625"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(02)00138-8"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5285"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23634"},{"key":"cit0067","first-page":"3","volume":"5","author":"Bossart J","year":"2005","journal-title":"Drug Delivery Technol"},{"key":"cit0068","unstructured":"innocore Pharmaceuticals. Synbiosys [cited 2021 Dec 16]. Available from: https:\/\/www.innocorepharma.com\/nl\/Synbiosys"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.10.026"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.05.279"},{"key":"cit0071","unstructured":"TCTMD. STENTYS Sirolimus-Eluting Stent receives CE marking: cardiovascular Research Foundation; 2014 [cited 2021 Dec 16]. Available from: https:\/\/www.tctmd.com\/news\/stentys-sirolimus-eluting-stent-receives-ce-marking"},{"key":"cit0072","unstructured":"Michaels B Drug-delivery technologies show some backbone: informa PLC; 2011 [cited 2021 Dec 16]. Available from: https:\/\/www.mddionline.com\/news\/drug-delivery-technologies-show-some-backbone"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.3109\/17453674.2016.1152853"},{"key":"cit0074","volume-title":"inventors; Innocore Technologies B.V., assignee. Biodegradable multi-block co-polymers","author":"Hissink CE","year":"2013"},{"key":"cit0075","volume-title":"Inventors; DSM IPASSETS B.V., assignee. Biodegradable polyesteramide copolymers for drug delivery","author":"Draaisma G","year":"2014"},{"key":"cit0076","first-page":"25","volume-title":"American Society of Retina Specialists","author":"Inc AP","year":"2019"},{"key":"cit0077","unstructured":"ClinicalTrials.gov. NCT03835884. A study assessing AR-13503 implant in subjects with nAMD or DME: U.S. National Library of Medicine; 2021 [updated 2021 Jul 28; cited 2021 Aug 03]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03835884"},{"key":"cit0078","volume-title":"Transforming ophthalmic care with sustained therapies. Ophthalmology Innovation Summit at AAO","author":"Ocular Therapeutix","year":"2016"},{"key":"cit0079","volume-title":"inventorsHydrogel drug delivery implants","author":"Jarrett P","year":"2016"},{"key":"cit0080","volume-title":"Jefferies virtual healthcare conference","author":"Mattessich A","year":"2020"},{"key":"cit0081","first-page":"26","author":"Yerxa B","year":"2017","journal-title":"International"},{"key":"cit0082","volume-title":"Sustained release ocular therapeutics. Ophthalmology Innovation Summit at ASRS","author":"Therapeutics R-V","year":"2019"},{"key":"cit0083","volume-title":"GB-102 clinical update: is every 6 month IVT dosing in wet AMD achievable? Ophthalmology Innovation Summit at AAO","author":"Semba CP","year":"2018"},{"key":"cit0084","volume-title":"Controlled release of Avastin\u00ae from the Tethadur\u2122 biodegradable matrix. Controlled Release Society Annual Meeting","author":"Kelly C","year":"2016"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S194234"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"cit0087","first-page":"260","volume-title":"The retinal pigment epithelium: function and disease","author":"Aguirre GD","year":"1998"},{"key":"cit0088","unstructured":"Bausch & Lomb Inc. Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg 2021 [cited 2021 Dec 16]. Available from: https:\/\/www.bausch.com\/ecp\/our-products\/rx-pharmaceuticals\/rx-pharmaceuticals\/retisert-fluocinolone-acetonide-intravitreal-implant-059-mg"},{"key":"cit0089","unstructured":"Drugs.com. Vitrasert 2021 [cited 2021 Dec 16]. Available from: https:\/\/www.drugs.com\/pro\/vitrasert.html"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.5.9.1039"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.032"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000291"},{"key":"cit0093","author":"Baker-Schena L","year":"2019","journal-title":"EyeNet Magazine"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1021\/cr200157d"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.3390\/gels7030130"},{"key":"cit0096","unstructured":"ClinicalTrials.gov. NCT03630315. CLN-0046: treatment of AMD subjects with OTX-TKI: u.S. National Library of Medicine; 2020 [cited 2021 Aug 05]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03630315"},{"key":"cit0097","unstructured":"Sanofi-aventis US ELIGARD (leuprolide acetate for injectable suspension) Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021731s005,021488s010,021379s010,021343s015lbl.pdf"},{"key":"cit0098","unstructured":"TOLMAR Inc. ATRIDOX\u00ae (doxycycline hyclate) 10% in the ATRIGEL\u00ae Delivery System for controlled release in subgingival application [July 18, 2022]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050751s015lbl.pdf"},{"key":"cit0099","unstructured":"DURECT Corporation Announces U.S. FDA Approval of POSIMIR\u00ae For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression Cupertino, CA: DURECT Corporation; 2021 [cited 2021 Dec 16]. Available from: https:\/\/investors.durect.com\/news-releases\/news-release-details\/durect-corporation-announces-us-fda-approval-posimirr-post"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00843-z"},{"issue":"9","key":"cit0101","first-page":"5394","volume":"60","author":"Noppari PS","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-017-0408-1"},{"key":"cit0103","unstructured":"Thakur R, Jones D Biodegradable implants for sustained intraocular delivery. ONdrugDelivery Magazine. 2018 [cited 2018 Jan 22]:[https:\/\/www.ondrugdelivery.com\/biodegradable-implants-sustained-intraocular-delivery-small-large-molecules\/"},{"issue":"13","key":"cit0104","first-page":"5273","volume":"55","author":"Spis M","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2498-y"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1955"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S19555"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19204"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172398299"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.09.002"},{"issue":"12","key":"cit0111","first-page":"4996","volume":"57","author":"Nimz EL","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"cit0112","first-page":"3025","volume":"53","author":"Gaudreault J","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1159\/000486145"},{"key":"cit0114","unstructured":"Partners M. Allergan and molecular partners announce two positive phase 3 clinical trials for Abicipar pegol 8 and 12-week regimens for the treatment in patients with neovascular age-related macular degeneration 2018 [cited 2018 Jul 19]:[https:\/\/www.molecularpartners.com\/allergan-and-molecular-partners-announce-two-positive-phase-3-clinical-trials-for-abicipar-pegol-8-and-12-week-regimens-for-the-treatment-in-patients-with-neovascular-age-related-macular-degeneration\/"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200204000-00002"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25307"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0607-8"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"key":"cit0122","volume-title":"Extended durability in exudative retinal diseases using the novel intravitreal anti-VEGF antibody biopolymer conjugate KSI-301. AAO Annual Meeting - Subspecialty Retina Day","author":"Wykoff CC","year":"2019"},{"key":"cit0123","unstructured":"Kodiak Sciences Inc. Kodiak Sciences announces top-line results from its initial phase 2b\/3 study of KSI-301 in patients with neovascular (wet) age-related macular degeneration 2022. Available from: https:\/\/kodiak.com\/press-releases\/kodiak-sciences-announces-top-line-results-from-its-initial-phase-2b-3-study-of-ksi-301-in-patients-with-neovascular-wet-age-related-macular-degeneration\/"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002614"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"issue":"7","key":"cit0126","first-page":"2277","volume":"56","author":"Loewenstein A","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0127","unstructured":"ClinicalTrials.gov. NCT02228304 study of the intravitreal implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD): u.S. National Library of Medicine; 2016 [cited 2021 Dec 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02228304"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15459"},{"key":"cit0129","unstructured":"Karth PA, Blumenkranz MS Update on intravitreal injection techniques: Johnson medical information, LLC; 2014 [cited 2021 Dec 15]. Available from: https:\/\/www.reviewofophthalmology.com\/article\/update-on-intravitreal-injection-techniques"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.03.013"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0128-y"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0063"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfaa081"},{"issue":"7","key":"cit0134","first-page":"2182","volume":"56","author":"Eaton JS","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0135","first-page":"1","volume-title":"Assessing ocular toxicology in laboratory animals","author":"V\u00e9zina M","year":"2013"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0721-9"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1177\/0192623307310955"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817741840"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12289"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1293\/tox.2015-0037"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320968079"},{"key":"cit0142","first-page":"1","volume-title":"Duane\u2019s foundations of clinical ophthalmology","author":"Sebag J","year":"2007"},{"key":"cit0143","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0149"},{"key":"cit0144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0108"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2006.10.002"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21566"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-0045-6"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/401956"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00601"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2450-1"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2007.0099"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.10.028"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00037"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.9b05176"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24480"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2023.2166927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T02:30:09Z","timestamp":1675823409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2023.2166927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":156,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1080\/17425247.2023.2166927"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2023.2166927","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}